Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Headache and migraine

Current and emerging evidence-based treatment options in chronic migraine: a narrative review.

Elio Clemente Agostoni; Piero Barbanti; Paolo Calabresi; Bruno Colombo; Pietro Cortelli; Fabio Frediani; Pietrangelo Geppetti; Licia Grazzi; Massimo Leone; Paolo Martelletti; Luigi Alberto Pini; Maria Pia Prudenzano; Paola Sarchielli; Gioacchino Tedeschi; Antonio Russo; Italian chronic migraine group

Originally published in The journal of headache and pain · 2019-08-30

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Background Chronic migraine is a disabling condition that is currently underdiagnosed and undertreated. In this narrative review, we discuss the future of chronic migraine management in relation to recent progress in evidence-based pharmacological treatment. Findings Patients with chronic migraine require prophylactic therapy to reduce the frequency of migraine attacks, but the only currently available evidence-based prophylactic treatment options for chronic migraine are topiramate and onabotulinumtoxinA. Improved prophylactic therapy is needed to reduce the high burden of chronic migraine in Italy. Monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) pathway of migraine pathogenesis have been specifically developed for the prophylactic treatment of chronic migraine. These anti-CGRP/R monoclonal antibodies have demonstrated good efficacy and excellent tolerability in phase II and III clinical trials, and offer new hope to patients who are currently not taking any prophylactic therapy or not benefitting from their current treatment. Conclusions Treatment of chronic migraine is a dynamic and rapidly advancing area of research.

Conclusions

Significant advances are currently being made in the prophylactic treatment of CM, which open new and promising scenarios in CM management. These advances should prompt us to rethink the approach to this devastating disease and empower us to be vigilant and continue scientific clinical research, bearing in mind that only a common, shared clinical and scientific management strategy will improve CM ascertainment, distinguish phenotypes and biological markers, shed light on neglected clinical governance areas, provide customised healthcare and tailored therapy, optimise economic resources allocation and reduce the…

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?